Anti‑inflammatory effect of ciclamilast in an allergic model involving the expression of PDE4B

Zheng,Xu‑Yang; Chen,Jun‑Chun; Xie,Qiang‑Min; Chen,Ji‑Qiang; Tang,Hui‑Fang

doi:10.3892/mmr.2019.9802

Anti‑inflammatory effect of ciclamilast in an allergic model involving the expression of PDE4B

Authors:
- Xu‑Yang Zheng
- Jun‑Chun Chen
- Qiang‑Min Xie
- Ji‑Qiang Chen
- Hui‑Fang Tang
View Affiliations

Affiliations: Department of Pediatrics, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310006, P.R. China, Department of Education, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310003, P.R. China, Zhejiang Respiratory Drugs Research Laboratory, School of Basic Medical Sciences, Zhejiang University, Hangzhou, Zhejiang 310058, P.R. China
Published online on: January 2, 2019 https://doi.org/10.3892/mmr.2019.9802
Pages: 1728-1738

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to investigate the potent inhibitory effects and possible biochemical basis of the novel phosphodiesterase 4 (PDE4) inhibitor ciclamilast, which is a derivative of piclamilast (RP 73401), on PDE4 and allergic inflammation. Ciclamilast was orally administered to allergic rats, their lungs and bronchoalveolar lavage fluid (BALF) were harvested, and their levels of inflammation and goblet cell hyperplasia, particularly cAMP‑PDE activity, and expression and distribution of PDE4 subtypes were determined. The results suggested that oral administration of ciclamilast significantly reduced the total leukocyte number and eosinophil number in BALF and suppressed lung histology changes, including the infiltration of inflammatory cells into the perivascular and peribronchial spaces, structural changes and goblet cell hyperplasia. For eosinophil infiltration, ciclamilast exhibited improved selectivity compared with piclamilast. Furthermore, ciclamilast significantly inhibited the upregulated activity of cAMP‑PDE and showed improved selective inhibition of the protein expression of PDE4B than piclamilast in a dose‑dependent manner. The mRNA expression of PDE4D was significantly increased in allergic rats, but PDE4B was not. PDE4B was mainly distributed in the cytoplasm, whereas PDE4D was mainly distributed in the cell membrane. The improved anti‑inflammatory activity of ciclamilast compared with piclamilast may be due to its higher level of inhibition of the activity, mRNA and protein expression of PDE4, particularly its effect on PDE4B.

View Figures

View References

1	Shu SJ, Lei XG, Liang JH, Song YH, Xu Q, Chen XD, Mao LG and Li ZG: The effects of second messenger cAMP and its relative components on the contraction of uterine smooth muscle of rat. Eur Rev Med Pharmacol Sci. 21:1709–1721. 2017.PubMed/NCBI
2	Sakkas LI, Mavropoulos A and Bogdanos DP: Phosphodiesterase 4 inhibitors in immune-mediated diseases: Mode of action, clinical applications, current and future perspectives. Curr Med Chem. 24:3054–3067. 2017. View Article : Google Scholar : PubMed/NCBI
3	Tang HF, Song YH, Chen JC, Chen JQ and Wang P: Upregulation of phosphodiesterase-4 in the lung of allergic rats. Am J Respir Crit Care Med. 71:823–828. 2005. View Article : Google Scholar
4	Ma D, Wu P, Egan RW, Billah MM and Wang P: Phosphodiesterase 4B gene transcription is activated by lipopolysaccharide and inhibited by interleukin-10 in human monocytes. Mol Pharmacol. 55:50–57. 1999. View Article : Google Scholar : PubMed/NCBI
5	Wang P, Wu P, Ohleth KM, Egan RW and Billah MM: Phosphodiesterase 4B2 is the predominant phosphodiesterase species and undergoes differential regulation of gene expression in human monocytes and neutrophils. Mol Pharmacol. 56:170–174. 1999. View Article : Google Scholar : PubMed/NCBI
6	Jin SL and Conti M: Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-alpha responses. Proc Natl Acad Sci USA. 99:7628–7633. 2002. View Article : Google Scholar : PubMed/NCBI
7	Singh SP, Barrett EG, Kalra R, Razani-Boroujerdi S, Langley RJ, Kurup V, Tesfaigzi Y and Sopori ML: Prenatal cigarette smoke decreases lung cAMP and increases airway hyperresponsiveness. Am J Respir Crit Care Med. 168:342–347. 2003. View Article : Google Scholar : PubMed/NCBI
8	Deng YM, Xie QM, Tang HF, Sun JG, Deng JF, Chen JQ and Yang SY: Effects of ciclamilast, a new PDE 4 PDE4 inhibitor, on airway hyperresponsiveness, PDE4D expression and airway inflammation in a murine model of asthma. Eur J Pharmacol. 547:125–135. 2006. View Article : Google Scholar : PubMed/NCBI
9	Tang HF, Chen JQ, Xie QM, Zheng XY, Zhu YL, Adcock I and Wang X: The role of PDE4 in pulmonary inflammation and goblet cell hyperplasia in allergic rats. Biochim Biophys Acta 1762. 525–532. 2006.
10	Xie QM, Chen JQ, Shen WH and Bian RL: Correlative changes of interferon-gamma and interleukin-4 between cortical layer and pulmonary airway of sensitized rats. Acta Pharmacol Sin. 23:248–252. 2002.PubMed/NCBI
11	Bian H, Zhang J, Wu P, Varty LA, Jia Y, Mayhood T, Hey JA and Wang P: Differential type 4 cAMP-specific phosphodiesterase (PDE4) expression and functional sensitivity to PDE4 inhibitors among rats, monkeys and humans. Biochem Pharmacol. 68:2229–2236. 2004. View Article : Google Scholar : PubMed/NCBI
12	Spina D: PDE4 inhibitors: Current status. Br J Pharmacol. 155:308–315. 2008. View Article : Google Scholar : PubMed/NCBI
13	Jin SL, Goya S, Nakae S, Wang D, Bruss M, Hou C, Umetsu D and Conti M: Phosphodiesterase 4B is essential for T(H)2-cell function and development of airway hyperresponsiveness in allergic asthma. J Allergy Clin Immunol. 126:1252–1259.e12. 2010. View Article : Google Scholar : PubMed/NCBI
14	Giembycz MA and Newton R: Harnessing the clinical efficacy of phosphodiesterase 4 inhibitors in inflammatory lung diseases: Dual-selective phosphodiesterase inhibitors and novel combination therapies. Handb Exp Pharmacol. 415–446. 2011. View Article : Google Scholar : PubMed/NCBI
15	Giembycz MA: Can the anti-inflammatory potential of PDE4 inhibitors be realized: Guarded optimism or wishful thinking? Br J Pharmacol. 155:288–290. 2008. View Article : Google Scholar : PubMed/NCBI
16	Ashton MJ, Cook DC, Fenton G, Karlsson JA, Palfreyman MN, Raeburn D, Ratcliffe AJ, Souness JE, Thurairatnam S and Vicker N: Selective type IV phosphodiesterase inhibitors as antiasthmatic agents. The syntheses and biological activities of 3-(cyclopentyloxy)-4-methoxybenzamides and analogues. J Med Chem. 37:1696–1703. 1994. View Article : Google Scholar : PubMed/NCBI
17	Souness JE, Maslen C, Webber S, Foster M, Raeburn D, Palfreyman MN, Ashton MJ and Karlsson JA: Suppression of eosinophil function by RP 73401, a potent and selective inhibitor of cyclic AMP-specific phosphodiesterase: Comparison with rolipram. Br J Pharmacol. 115:39–46. 1995. View Article : Google Scholar : PubMed/NCBI
18	Cooper N, Teixeira MM, Warneck J, Miotla JM, Wills RE, Macari DM, Gristwood RW and Hellewell PG: A comparison of the inhibitory activity of PDE4 inhibitors on leukocyte PDE4 activity in vitro and eosinophil trafficking in vivo. Br J Pharmacol. 126:1863–1871. 1999. View Article : Google Scholar : PubMed/NCBI
19	Favot L, Keravis T and Lugnier C: Modulation of VEGF-induced endothelial cell cycle protein expression through cyclic AMP hydrolysis by PDE2 and PDE4. Thromb Haemost. 92:634–645. 2004. View Article : Google Scholar : PubMed/NCBI
20	Favot L, Keravis T, Holl V, Le Bec A and Lugnier C: VEGF-induced HUVEC migration and proliferation are decreased by PDE2 and PDE4 inhibitors. Thromb Haemost. 90:334–343. 2003. View Article : Google Scholar : PubMed/NCBI
21	Peter D, Jin SL, Conti M, Hatzelmann A and Zitt C: Differential expression and function of phosphodiesterase 4 (PDE4) subtypes in human primary CD4+ T cells: Predominant role of PDE4D. J Immunol. 178:4820–4831. 2007. View Article : Google Scholar : PubMed/NCBI
22	Beeh KM, Beier J, Lerch C, Schulz AK and Buhl R: Effects of piclamilast, a selective phosphodiesterase-4 inhibitor, on oxidative burst of sputum cells from mild asthmatics and stable COPD patients. Lung. 182:369–377. 2004. View Article : Google Scholar : PubMed/NCBI
23	Aoki M, Kobayashi M, Ishikawa J, Saita Y, Terai Y, Takayama K, Miyata K and Yamada T: A novel phosphodiesterase type 4 inhibitor, YM976 (4-(3-chlorophenyl)-1,7-diethylpyrido[2,3-d]pyrimidin-2(1H)-one), with little emetogenic activity. J Pharmacol Exp Ther. 295:255–260. 2000.PubMed/NCBI
24	de Visser YP, Walther FJ, Laghmani EH, van Wijngaarden S, Nieuwland K and Wagenaar GT: Phosphodiesterase-4 inhibition attenuates pulmonary inflammation in neonatal lung injury. Eur Respir J. 31:633–644. 2008. View Article : Google Scholar : PubMed/NCBI
25	de Visser YP, Walther FJ, Laghmani el H, Steendijk P, Middeldorp M, van der Laarse A and Wagenaar GT: Phosphodiesterase 4 inhibition attenuates persistent heart and lung injury by neonatal hyperoxia in rats. Am J Physiol Lung Cell Mol Physiol. 302:L56–L67. 2012. View Article : Google Scholar : PubMed/NCBI
26	Souness JE, Griffin M, Maslen C, Ebsworth K, Scott LC, Pollock K, Palfreyman MN and Karlsson JA: Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNF alpha generation from human monocytes by interacting with a ‘low-affinity’ phosphodiesterase 4 conformer. Br J Pharmacol. 118:649–658. 1996. View Article : Google Scholar : PubMed/NCBI
27	Raeburn D, Underwood SL, Lewis SA, Woodman VR, Battram CH, Tomkinson A, Sharma S, Jordan R, Souness JE, Webber SE and Karlsson JA: Anti-inflammatory and bronchodilator properties of RP 73401, a novel and selective phosphodiesterase type IV inhibitor. Br J Pharmacol. 113:1423–1431. 1994. View Article : Google Scholar : PubMed/NCBI
28	Holbrook M, Gozzard N, James T, Higgs G and Hughes B: Inhibition of bronchospasm and ozone-induced airway hyperresponsiveness in the guinea-pig by CDP840, a novel phosphodiesterase type 4 inhibitor. Br J Pharmacol. 118:1192–1200. 1996. View Article : Google Scholar : PubMed/NCBI
29	Bundschuh DS, Eltze M, Barsig J, Wollin L, Hatzelmann A and Beume R: In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor. J Pharmacol Exp Ther. 297:280–290. 2001.PubMed/NCBI
30	Wollin L, Bundschuh DS, Wohlsen A, Marx D and Beume R: Inhibition of airway hyperresponsiveness and pulmonary inflammation by roflumilast and other PDE4 inhibitors. Pulm Pharmacol Ther. 19:343–352. 2006. View Article : Google Scholar : PubMed/NCBI
31	Sun JG, Deng YM, Wu X, Tang HF, Deng JF, Chen JQ, Yang SY and Xie QM: Inhibition of phosphodiesterase activity, airway inflammation and hyperresponsiveness by PDE4 inhibitor and glucocorticoid in a murine model of allergic asthma. Life Sci. 79:2077–2085. 2006. View Article : Google Scholar : PubMed/NCBI
32	Ji H, Xie QM and Chen JQ: Comparison of piclamilast with ciclamilast in bronchodilating and antiallergic effects. Zhejiang Da Xue Xue Bao Yi Xue Ban. 32:274–278. 2003.(In Chinese). PubMed/NCBI
33	Chen JC, Chen JQ, Xie QM and Zhu YL: Selective inhibition of purified human phosphodiesterase 4A expressed in yeast cell GL62 by ciclamilast, piclamilast, and rolipram. Acta Pharmacol Sin. 25:1171–1175. 2004.PubMed/NCBI
34	Thompson WJ, Ashikaga T, Kelly JJ, Liu L, Zhu B, Vemavarapu L and Strada SJ: Regulation of cyclic AMP in rat pulmonary microvascular endothelial cells by rolipram-sensitive cyclic AMP phosphodiesterase (PDE4). Biochem Pharmacol. 63:797–807. 2002. View Article : Google Scholar : PubMed/NCBI
35	Ahlstrom M, Pekkinen M, Huttunen M and Lamberg-Allardt C: Dexamethasone down-regulates cAMP-phosphodiesterase in human osteosarcoma cells. Biochem Pharmacol. 69:267–275. 2005. View Article : Google Scholar : PubMed/NCBI
36	Barnes PJ and Adcock IM: Glucocorticoid resistance in inflammatory diseases. Lancet. 373:1905–1917. 2009. View Article : Google Scholar : PubMed/NCBI
37	Milara J, Navarro A, Almudever P, Lluch J, Morcillo EJ and Cortijo J: Oxidative stress-induced glucocorticoid resistance is prevented by dual PDE3/PDE4 inhibition in human alveolar macrophages. Clin Exp Allergy. 41:535–546. 2011. View Article : Google Scholar : PubMed/NCBI
38	Tiwari S, Dong H, Kim EJ, Weintraub L, Epstein PM and Lerner A: Type 4 cAMP phosphodiesterase (PDE4) inhibitors augment glucocorticoid-mediated apoptosis in B cell chronic lymphocytic leukemia (B-CLL) in the absence of exogenous adenylyl cyclase stimulation. Biochem Pharmacol. 69:473–483. 2005. View Article : Google Scholar : PubMed/NCBI
39	Dong H, Zitt C, Auriga C, Hatzelmann A and Epstein PM: Inhibition of PDE3, PDE4 and PDE7 potentiates glucocorticoid-induced apoptosis and overcomes glucocorticoid resistance in CEM T leukemic cells. Biochem Pharmacol. 79:321–329. 2010. View Article : Google Scholar : PubMed/NCBI